TP53 and neoplasm: This analysis revealed considerable differences in the odds ratios in subgroups stratified by tumor size (pT1 vs. pT2-4), stage (0–1 vs. 2–4), grade (pG1–2 vs. pG3), progesterone receptor (PR) status, Ki67 status (≤10% vs. >10% Ki67-positive tumor cells), and p53 status (Figure 2).